

## Gender Differences in Perception of Dyspnea and Spirometric Abnormalities in Asthma

Dr. Prashanth Thaviti<sup>1</sup>, Dr. K. Ramesh Kumar<sup>2\*</sup>, Dr. Narra Sweta<sup>3</sup>, Dr. A. Siva Prasad<sup>4</sup><sup>1</sup>Senior Resident, Department of Pulmonary Medicine, Bhaskar Medical College, Survey No. 156 To 162, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075, India<sup>2</sup>Professor & HOD, Department of Pulmonary Medicine, Bhaskar Medical College, Survey No. 156 To 162, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075, India<sup>3</sup>Junior Resident, Department of Pulmonary Medicine, Bhaskar Medical College, Survey No. 156 To 162, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075, India<sup>4</sup>Assistant Professor, Department of Pulmonary Medicine, Bhaskar Medical College, Survey No. 156 To 162, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075, IndiaDOI: [10.36347/sjams.2023.v11i09.009](https://doi.org/10.36347/sjams.2023.v11i09.009)

| Received: 30.07.2023 | Accepted: 06.09.2023 | Published: 11.09.2023

**\*Corresponding author:** Dr. K. Ramesh Kumar

Professor &amp; HOD, Department of Pulmonary Medicine, Bhaskar Medical College, Survey No. 156 To 162, Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075, India

**Abstract****Original Research Article**

Asthma prevalence and severity have gender preference in various ages. In children, boys have an increased prevalence of asthma. In adults, women have an increased prevalence and severity of asthma. Sex hormones, genetic, and epigenetic variations, social, and environmental factors, and responses to asthma therapeutics are important factors that have an impact on the severity and response of symptoms.

**Keywords:** Asthma, Fev1, Gender.

Copyright © 2023 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

### SUMMARY

The present study was conducted in department of pulmonary medicine Bhaskar medical college, Hyderabad in June 2022- June 2023. Based on our present study it was concluded that Perception of dyspnea was higher among females than males. Fev1 was lower in females compared to males. Asthma was also associated with comorbidities like allergic rhinitis, obesity, gastro esophageal reflux disease. Females expressed more concern about the disease and felt a greater impairment of their Quality of life, impacting their usual daily activities and producing more discomfort and anxiety/depression. Female sex hormones are hypothesized to affect these outcomes, however other factors have been claimed, such as different behaviors of asthmatic males and females — females have shown a lower threshold for healthcare contact requirement.

**AIM**

Gender Differences in Perception of Dyspnea and Spirometric Abnormalities in Asthma

**OBJECTIVES**

1. To study Gender differences in spirometric

abnormalities in Asthma.

2. To study Gender differences of spirometric abnormalities in Asthma.

### METHODS

Informed and written consent will be taken from the patient/guardian. Pulmonary function tests and perception of dyspnea by MMRC SCALE are assessed and results are analyzed.

**STUDY POPULATION**

All Asthma patients who come to Department of Pulmonary Medicine, Bhaskar Medical College and General Hospital.

**Sample Size:** 50 Male asthmatic patients and 50 female Asthmatic patients.**Inclusion Criteria:**

All the MALE asthmatic and FEMALE Asthmatic patients between the age 20 -55 years.

**Exclusion Criteria:**

1. Critically ill patients who might need emergency medical care.

2. ASTHMATICS below 20 and above 55 years.
3. Patients who do not consent to be a part of the study.
4. Patients with cardiovascular comorbidities.

**STUDY PERIOD:** Over a period of 12 months from June 2022 to June 2023.

**STUDY DESIGN:** Cross-sectional study

**DATA ANALYSIS (EXPECTED OUTCOME):** Data will be subjected to the ANOVA statistical method using SPSS software 2010.

**ETHICAL IMPLICATIONS**

- The study subjects will be selected following inclusion and exclusion criteria.
- Written & informed consent will be taken.
- Every patient will be completely explained about the study and related procedures and their importance and complications in their understandable language.

**FINANCIAL IMPLICATIONS:**

- Funding—none

- Expenses if any will be incurred by me.

**INVESTIGATIONS:**

- Chest x ray
- Pulmonary function test: Spirometry

**STATISTICAL ANALYSIS:**


All the information obtained from our study population was collected and recorded in master chart. Statistical significance was analysed by the Chi-square test and logistic regression analysis was performed with SPSS software to assess the independent association of variables found to be significant in univariate analysis.

- If the Pvalue is between 0.000 to 0.010, it is considered to be significant at level 1- Highly Significant
- If the Pvalue is between 0.011 to 0.050, it is considered to be significant at level 5- Significant
- If the Pvalue is between 0.051-1.000, it is considered insignificant at level 5- Not Significant.

**RESULTS**

**Table 1: Sex Distribution of Study Population**


SEX	PERCENT
MALE	50
FEMALE	50
TOTAL	100



**Table 2: Age Distribution of the Study**

**AGE DISTRIBUTION**


AGE	NUMBER OF PATIENTS
20-30	28
30-40	36
40-50	20
>50	16
TOTAL	100




**Table 3: Severity According to New Gina Guidelines**

		FEV 1 % CATEGORY			
		Frequency	percent	Valid percent	Cumulative percent
VALID	<60%	13	13.0	13.0	13.0
	60-79%	61	61.0	61.0	74.0
	80 %AND ABOVE	26	26.0	26.0	100.0
	TOTAL	100	100.0	100.0	

**Table 4: Association between Fev1 and Gender**




Association between severity of FEV1% and Gender						
		FEV1%			Total	
		<60	60-79	80 and above		Test of significance
Gender	MALE	3	24	23	50	$\chi^2=21.9, df=2, p=0.008$
	FEMALE	10	37	3	50	
Total		13	61	26	100	



**Table 5: Association between Asthma and Other Comorbid Conditions**

COMORBID CONDITIONS	PERCENTAGE
ALLERGIC RHINITIS	34
SINUSITIS	7
ECZEMA	6
GERD	4
OBESITY	5
NONE	44
<b>TOTAL</b>	<b>100</b>

**Table 6: MMRC Grading of Population**

SEX * MMRC GRADE Crosstabulation			MMRC GRADE					Total
			0	1	2	3	4	
SEX	FEMALE	Count	1	4	11	20	14	50
		% within SEX	2.0%	8.0%	22.0%	40.0%	28.0%	100.0%
	MALE	Count	3	24	11	10	2	50
		% within SEX	6.0%	48.0%	22.0%	20.0%	4.0%	100.0%
Total		Count	4	28	22	30	16	100
		% within SEX	4.0%	28.0%	22.0%	30.0%	16.0%	100.0%

**Table 7: Asthma Control Questionarre**

ACQ SCORE	MALES	FEMALES
< 4	28	24
>4	22	26

## DISCUSSION

In our study, a total of 100 cases were selected, out of them 50 were male and 50 were female. India's prevalence of asthma is 2.05% with almost equal sex proportion of male 1.09% and female 0.96%. Overall, females (9.5%) were more than males (7.0%). Although the female-to-male balance changes over development, asthma is less common in females than males during childhood, but more common in females than males during adulthood because of hormonal factors. This was a study conducted in Bhaskar Medical College Hospital with 100 consecutive patients. The purpose of the study was to find out if there were any Gender-specific differences in the perception of dyspnea and spirometric abnormalities.

Gender was compared with the severity of bronchial asthma and found that most of the females were presented with severe asthma when compared to males showing a significant correlation (pvalue 0.008). In various literatures, asthma in women was reported to

be more severe and associated with higher health care use. After puberty, a gender switch occurs, and asthma becomes more prevalent and severe in women. Girls who mature early, and pregnant women are likely to be exposed to higher estrogen levels, and greater cumulative hormonal exposure of sex hormones, which place them at higher risk for asthma development later in life. In contrast, oral contraceptive may be protective and decrease the risk of exacerbation in asthmatic women.

## CONCLUSION

Based on our present study it was concluded that:

- Asthma was also associated with comorbidities like allergic rhinitis, obesity, gastroesophageal reflux disease.
- Perception of dyspnea was higher among females than males.
- Fev 1% was lower in females compared to males.
- Moreover, females expressed more concern

about the disease and felt a greater impairment of their Quality of life, impacting their usual daily activities and producing more discomfort and anxiety/depression.

- Female sex hormones are hypothesized to affect these outcomes, however, other factors have been claimed, such as different behaviors of asthmatic males and females—females have shown a lower threshold for healthcare contact requirement.
- Different adherence to medications—females seem to need more encouragement and education than males regarding the correct use of inhalers and different attitudes of caregivers toward males and females—with for example females undergoing less spirometry testing. Concerning medications, it may be interesting to report that our female population showed a trend toward a greater use of OCS and a lower use of pure inhaled medications.

## REFERENCES

- Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI) Global Strategy for Asthma Management and Prevention. Bethesda (MD): Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI); 2006. p. 339. Available from: <http://www.ginasthma.com>.
- Jay Grossman Oneairway, onedisease Chest 1997; 111:11S-16S.
- Philip, G., Malmstrom, K., Hampel Jr, F. C., Weinstein, S. F., LaForce, C. F., Ratner, P. H., ... & Montelukast Spring Rhinitis Study Group. (2002). Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. *Clinical & Experimental Allergy*, 32(7), 1020-1028.
- Marketos, S. G., & Ballas, C. N. (1982). Bronchial asthma in the medical literature of Greek antiquity. *Journal of Asthma*, 19(4), 263-269.
- CDC. [Accessed Dec 2]; National Health Interview Survey (NHIS) data. <http://www.cdc.gov/asthma/nhis/2012/data.htm.2>.
- Sullivan, P. W., Ghushchyan, V. H., Slejko, J. F., Belozeroff, V., Globe, D. R., & Lin, S. L. (2011). The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. *Journal of allergy and clinical immunology*, 127(2), 363-369.
- Moorman, J. E., Akinbami, L. J., Bailey, C. M., Zahran, H. S., King, M. E., Johnson, C. A., & Liu, X. (2012). National surveillance of asthma: United States, 2001-2010. *Vital & health statistics. Series 3, Analytical and epidemiological studies*, (35), 1-58.
- Akinbami, O. J. (2012). *Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010* (No. 94). US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
- Patel, M., Pilcher, J., Reddel, H. K., Qi, V., Mackey, B., Tranquilino, T., ... & SMART Study Group. (2014). Predictors of severe exacerbations, poor asthma control, and  $\beta$ -agonist overuse for patients with asthma. *The Journal of Allergy and Clinical Immunology: In Practice*, 2(6), 751-758.
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*, 390, 1211-1259.
- Schatz, M., & Camargo Jr, C. A. (2003). The relationship of sex to asthma prevalence, health care utilization, and medications in a large managed care organization. *Annals of allergy, asthma & immunology*, 91(6), 553-558.
- El-Husseini, Z. W., Gosens, R., Dekker, F., & Koppelman, G. H. (2020). The genetics of asthma and the promise of genomics-guided drug target discovery. *The Lancet Respiratory Medicine*, 8(10), 1045-1056.
- Han, Y. Y., Forno, E., & Celedón, J. C. (2020). Sex steroid hormones and asthma in a nationwide study of US adults. *American journal of respiratory and critical care medicine*, 201(2), 158-166.
- Gomez, J. L. (2019). Epigenetics in asthma. *Current allergy and asthma reports*, 19, 1-6.
- Wang, E., Wechsler, M. E., Tran, T. N., Heaney, L. G., Jones, R. C., Menzies-Gow, A. N., ... & Price, D. B. (2020). Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. *Chest*, 157(4), 790-804.
- Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., ... & Wenzel, S. E. (2007). Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program. *Journal of Allergy and Clinical Immunology*, 119(2), 405-413.
- Wu, W., Bleecker, E., Moore, W., Busse, W. W., Castro, M., Chung, K. F., ... & Wenzel, S. E. (2014). Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. *Journal of Allergy and Clinical Immunology*, 133(5), 1280-1288.